Literature DB >> 16410188

Cardiac lesions induced by neuroleptic drugs in the rabbit.

D Belhani1, D Frassati, R Mégard, P Tsibiribi, B Bui-Xuan, A Tabib, L Fanton, D Malicier, J Descotes, Q Timour.   

Abstract

Sudden death seems to be more frequent following treatment with neuroleptic drugs in patients with pre-existing cardiac lesions, especially dilated and hypertrophic myocardiopathy. The present study was undertaken to confirm the hypothesis that myocardial lesions can be induced by neuroleptic drugs. Eight groups of 6 New-Zealand White rabbits were treated for 3 months: group I: controls (saline); group II: 15 mg/kg/day amisulpride; group III: 0.20 mg/kg/day haloperidol; group IV: 3 mg/kg/day levomepromazine; group V: 0.30 mg/kg/day olanzapine; group VI: 1.0 mg/kg risperidone, every 15 days; group VII: levomepromazine+haloperidol, same dose levels as single treatments; group VIII: levomepromazine+risperidone, same dose levels as single treatments. The hearts were immediately weighted and fixed, and paraffin sections were prepared and examined. Ventricular hypertrophy was observed following treatment with olanzapine and was still more marked with the combinations levomepromazine+haloperidol and levomepromazine+risperidone. Amisulpride and haloperidol induced necrotic lesions and levomepromazine, endocardial fibrosis. There was a lack of severe cardiac lesions following treatment with risperidone. The observed cardiac lesions can be compared to those seen in toxic myocarditis. These findings confirm the hypothesis that some neuroleptic drugs induce myocardial lesions. Further studies are warranted to demonstrate the effects of treatments of longer duration and the influence of pre-existing cardiac lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16410188     DOI: 10.1016/j.etp.2005.09.003

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  7 in total

Review 1.  How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

Authors:  Hg Laverty; C Benson; Ej Cartwright; Mj Cross; C Garland; T Hammond; C Holloway; N McMahon; J Milligan; Bk Park; M Pirmohamed; C Pollard; J Radford; N Roome; P Sager; S Singh; T Suter; W Suter; A Trafford; Pga Volders; R Wallis; R Weaver; M York; Jp Valentin
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity.

Authors:  Liliang Li; Pan Gao; Xinru Tang; Zheng Liu; Mengying Cao; Ruoyu Luo; Xiaoqing Li; Jing Wang; Xinyi Lin; Chao Peng; Zhihong Li; Jianhua Zhang; Xian Zhang; Zhonglian Cao; Yunzeng Zou; Li Jin
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

3.  Olanzapine Induced Dilated Cardiomyopathy.

Authors:  Beeresha Puttegowda; Joseph Theodore; Ramesh Basappa; Manjunath Cholenally Nanjappa
Journal:  Malays J Med Sci       Date:  2016-03

4.  Sudden death of cardiac origin and psychotropic drugs.

Authors:  Quadiri Timour; Dominique Frassati; Jacques Descotes; Philippe Chevalier; Georges Christé; Mohamed Chahine
Journal:  Front Pharmacol       Date:  2012-05-10       Impact factor: 5.810

5.  Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.

Authors:  Torkel Vang; Mary Rosenzweig; Christina Hedegaard Bruhn; Christoffer Polcwiartek; Jørgen Kim Kanters; Jimmi Nielsen
Journal:  BMC Psychiatry       Date:  2016-03-17       Impact factor: 3.630

Review 6.  It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease.

Authors:  Mark Sweeney; Gabor Foldes
Journal:  Front Cardiovasc Med       Date:  2018-10-30

7.  Impairment of the cardiac ejection fraction by blocking dopamine D2 receptors induced by long-acting injectable antipsychotic treatment.

Authors:  Liana Dehelean; Ileana Marinescu; Puiu Olivian Stovicek; Ana Maria Romoşan; Radu Ştefan Romoşan; Rita Bálint; Bianca Oana Bucatoş; Andra Vera Livia Ciobanu; Mariana Bondrescu; Dragoş Marinescu; Marinela Minodora Manea; Valentina Oana Buda; Minodora Andor; Adela Magdalena Ciobanu
Journal:  Rom J Morphol Embryol       Date:  2021 Apr-Jun       Impact factor: 1.033

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.